Feature | EP Mapping and Imaging Systems | May 15, 2019 | Dave Fornell, Editor

Electromechanical Wave Imaging Can Correctly Localize Cardiac Arrhythmias

New ultrasound imaging technology can noninvasively electromap the heart prior to ablations

Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.

Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.


May 15, 2019 — A new study shows electromechanical wave imaging is capable of localizing arrhythmias including atrial tachycardia (AT), atrial flutter (AFL), premature ventricular complexes (PVC), and accessory pathways (AP) in Wolff-Parkinson-White syndrome prior to catheter ablation. The double-blinded study for this new technology was presented as a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Diagnosis and localization of arrhythmias are critical for decision making and treatment planning prior to cardiac ablation. The 12 lead ECG is the main noninvasive tool used to localize arrhythmias, however it can be limited in specificity and subject to interobserver variability. Electromechanical Wave Imaging (EWI) is a novel, high frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm.

In this study, EWI was able to correctly predict 96% of arrhythmia locations as compared with 71% for 12-lead ECG analyses (unadjusted for arrhythmia type: OR: 11.8; 95% CI: 2.2-63.2; p=0.004; adjusted for arrhythmia type: OR: 12.1; 95% CI: 2.3-63.2; p=0.003). There was significant inter-observer variability amongst ECG reads.

Ongoing efforts include incorporating EWI isochrones into 3-D anatomical maps prior to ablation to determine whether EWI can affect clinical outcomes, said Elaine Wan, M.D., FHRS, the Esther Aboodi Assistant Professor of Medicine in Cardiology and Cardiac Electrophysiology at Columbia University Medical Center. She explained this includes reducing procedure time and radiation dose, in addition to exploring EWI with transesophageal, intracardiac, and 3-D ultrasound.

In the study, patients presenting for catheter ablation of AT, AFL, PVCs, or an AP underwent transthoracic EWI and 12 lead ECG prior to the ablation. 67 patients were consented, 12 patients were excluded due to withdrawal of consent, poor imaging or not being in the arrhythmia at time of imaging. There were 55 patients who underwent EWI (mean age 56.0±2.3 years, 71% male). Of these, 22% had WPW, 20% had PVCs, 13% had AT and 45% had AFL. Six blinded clinical electrophysiologists predicted arrhythmia origins based on ECG alone. EWI isochrone processing was blinded to all clinical data except arrhythmia type. Operating physicians were blinded to EWI isochrones. EWI and ECG predictions were compared to arrhythmia location as determined by 3-D electroanatomic mapping and ablation using a standardized 21 segment cardiac model.

All the HRS 2019 late-breaking studies 

Link to other HRS 2019 news

 

 


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now